A novel phenotype-based approach for systematically screening antiproliferation metallodrugs

Area of Science:

• Metallodrug discovery
• Zebrafish model organism research
• Cancer research

Background:

• Ruthenium (Ru) compounds offer lower toxicity and better water solubility than cisplatin, presenting potential as antitumor metallodrugs.
• Zebrafish serve as a whole-organism model for screening drug candidates due to their physiological similarities to humans and rapid development.
• Phenotypic screening in vivo can identify compounds with anti-proliferative effects, guiding further drug development.

Purpose of the Study:

• To screen novel ruthenium compounds for anti-proliferative activity using a zebrafish whole-organism model.
• To investigate the mechanism of action of promising ruthenium derivatives, including their effect on cell apoptosis.
• To evaluate the efficacy of the zebrafish model in identifying phenotype-based antiproliferation metallodrugs.

Main Methods:

• Zebrafish embryos were exposed to cisplatin and various ruthenium derivatives.
• Phenotypic changes, specifically fin development, were observed and quantified.
• TUNEL assays and immunostaining were used to assess apoptosis in fin mesenchymal cells.
• The activation of P53 pathways and apoptosis induction in human hepatoma cells were examined for specific Ru compounds.

Main Results:

• Cisplatin and [Ru(terpy)(bpy)Cl]Cl induced significant phenotypic effects, including fin reduction, in zebrafish embryos.
• A modified ruthenium compound, [Ru(terpy)(dmbpy)Cl]Cl, also exhibited fin-reduction phenotypes.
• Treatment with cisplatin, [Ru(terpy)(bpy)Cl]Cl, and [Ru(terpy)(dmbpy)Cl]Cl resulted in apoptosis of proliferating fin cells.
• [Ru(terpy)(bpy)Cl]Cl activated P53-dependent and independent pathways, inducing apoptosis in human hepatoma cells.

Conclusions:

• The zebrafish model is effective for phenotype-based screening of antiproliferation metallodrugs.
• Specific ruthenium derivatives, [Ru(terpy)(bpy)Cl]Cl and [Ru(terpy)(dmbpy)Cl]Cl, demonstrate anti-proliferative activity via apoptosis induction.
• Ruthenium-based metallodrugs show promise as alternatives to cisplatin for cancer therapy.